The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -5,625,749 | -4,553,953 | -5,407,470 | -12,266,429 |
| Stock-based compensation expense | 1,356,389 | 1,541,675 | 1,800,614 | 2,704,372 |
| Change in estimated fair value of warrant liability | - | 0 | 0 | 0 |
| Gain on settlement of warrant liability | - | 0 | 0 | - |
| Loss on issuance of related party convertible notes payable at fair value | - | 0 | 0 | 0 |
| Change in estimated fair value of related party convertible notes payable | - | 0 | 0 | 0 |
| Issuance of restricted shares in exchange for services | 138,500 | - | - | - |
| Interest accrued on license payable | 5,062 | 5,062 | 15,188 | - |
| Prepaid assets and other current assets | -98,552 | -35,241 | 323,334 | -370,375 |
| Other assets | 0 | 0 | 0 | -110,548 |
| Proceeds from initial public offering, net of underwriting discounts and commissions | - | 0 | 0 | - |
| Accrued interest | - | 0 | -81,082 | 10,125 |
| Accounts payable | -322,797 | 185,555 | -1,828,207 | 1,130,116 |
| Payment of offering costs related to initial public offering | - | 0 | 0 | - |
| Accrued compensation | 297,509 | -257,979 | -541,835 | 499,669 |
| Proceeds from issuances of related party convertible notes payable | - | 0 | 0 | 0 |
| Other accrued expenses | -964,793 | -691,644 | -311,583 | -1,351,277 |
| Proceeds from issuance of related party short-term loan | - | 0 | 0 | - |
| Net cash used in operating activities | -5,017,327 | -3,736,043 | -6,677,709 | -8,792,501 |
| Payment of related party short-term loan | - | 0 | 0 | - |
| Proceeds from the exercise of stock options | - | 0 | 0 | 34,115 |
| Proceeds from issuance of shares of common stock under underwritten public offering, net of underwriting discounts and offering costs | - | 0 | 15,573,966 | - |
| Proceeds from issuance of shares of common stock under june 2025 private placement, net | - | 0 | -29,084 | 4,621,546 |
| Proceeds from sale of shares under at-the-market facility, net | 519,624 | 0 | 1,663,236 | 2,163,100 |
| Payment of taxes from withholding of common stock on settlement of restricted stock units | 527,716 | - | - | - |
| Deferred offering costs | 0 | 29,297 | 98,302 | 175,226 |
| Net cash used in financing activities | -8,092 | -29,297 | 17,109,816 | 6,643,535 |
| Net change in cash and cash equivalents | -5,025,419 | -3,765,340 | 10,432,107 | -2,148,966 |
| Cash and cash equivalents, beginning of period | 13,159,423 | 16,924,763 | 8,641,622 | - |
| Cash and cash equivalents, end of period | 8,134,004 | 13,159,423 | 16,924,763 | - |
ACTUATE THERAPEUTICS, INC. (ACTU)
ACTUATE THERAPEUTICS, INC. (ACTU)